GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (STU:3XV) » Definitions » EPS (Diluted)

Xvivo Perfusion AB (STU:3XV) EPS (Diluted) : €0.30 (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xvivo Perfusion AB EPS (Diluted)?

Xvivo Perfusion AB's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €0.06. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.30.

Xvivo Perfusion AB's EPS (Basic) for the three months ended in Mar. 2024 was €0.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.30.

Xvivo Perfusion AB's EPS without NRI for the three months ended in Mar. 2024 was €0.06. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was €0.30.

During the past 12 months, Xvivo Perfusion AB's average EPS without NRIGrowth Rate was 253.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, Xvivo Perfusion AB's highest 3-Year average EPS without NRI Growth Rate was 51.00% per year. The lowest was -42.60% per year. And the median was 12.30% per year.


Xvivo Perfusion AB EPS (Diluted) Historical Data

The historical data trend for Xvivo Perfusion AB's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB EPS (Diluted) Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 -0.16 0.03 0.06 0.27

Xvivo Perfusion AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.02 0.01 0.21 0.06

Competitive Comparison of Xvivo Perfusion AB's EPS (Diluted)

For the Medical Devices subindustry, Xvivo Perfusion AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's PE Ratio distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's PE Ratio falls into.



Xvivo Perfusion AB EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Xvivo Perfusion AB's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(8.208-0)/29.935
=0.27

Xvivo Perfusion AB's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(2.013-0)/31.499
=0.06

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB  (STU:3XV) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Xvivo Perfusion AB EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (STU:3XV) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB (STU:3XV) Headlines

No Headlines